> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Probes Burn Reports with Migraine Patch Users
- URL: https://www.fdaweb.com/fda-probes-burn-reports-with-migraine-patch-users/
- Published: 2016-06-02T12:00:00.000Z
- Updated: 2026-09-14T21:06:52.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5135824

FDA says it is investigating reports of serious burns and potential permanent scarring in users of NuPathe’s battery-powered Zecuity (sumatriptan iontophoretic transdermal system) patch, indicated for treating acute migraines with or without aura in adults. “We are investigating the cause and extent of these serious side effects and will update the public with new information when our review is complete,” an agency drug [safety notice](http://www.fda.gov/Drugs/DrugSafety/ucm504588.htm?ref=fdaweb.com) says.  

In 2013, the agency approved the single-use patch that delivers sumatriptan through the skin, but marketing of the product did not begin until 9/2015\. Since then, there have been a large number of patients who have reported experiencing burns or scars on the skin where the patch was worn, according to FDA. “The reports included descriptions of severe redness, pain, skin discoloration, blistering, and cracked skin,” it says. “As a result, we are investigating these serious adverse events to determine whether future regulatory action is needed.”  

FDA advises that patients who experience moderate to severe pain at the Zecuity patch site should immediately remove it to avoid possible burns or scarring. They should also not bathe, shower, or swim while wearing the patch.